Saturday, September 30, 2023
Saturday, September 30, 2023

Contact us 561.316.3330

KA Imaging Signs Australian Distributor – Regional Health Care Group

Medical distribution company Regional Health Care Group (RHCG) will now be bringing KA Imaging’s innovative X-ray technologies to Australia and New Zealand.

This agreement ensures sole rights to RHCG as KA Imaging’s distributor.

“This is a fantastic opportunity for KA Imaging that moves us towards fulfilling our vision of innovative X-ray everywhere. We are thrilled to be expanding our business to the Australian market with our point-of-care, dual-energy solution,” said Amol Karnick, President and CEO.

In the past few months, KA Imaging has expanded its global presence. In addition to Australia, the company recently announced distributors in the United States and Mexico.

RHCG has been servicing the needs of the medical industry in Australia for more than 40 years. They are highly regarded in all clinical settings as a provider of medical consumables, contrast media and quality capital equipment.

“We are very excited to join forces with Canadian X-ray innovators KA Imaging. We are confident that the Reveal™ 35C technology will benefit the Australian healthcare system, especially with the results shown in current trials for detecting lung cancer and COVID-19 pneumonia,” said Stephen Doorey, General Manager of RHCG.

Healthcare is primarily funded through a public Medicare program in Australia and is provided to patients in both public and private sector hospitals and clinics. According to RHCG, the market size for diagnostic imaging services is said to be more than a $4B AUD.

Reveal 35C is the world’s first and only single exposure dual-energy flat panel X-ray detector that can be used in fixed, mobile, and portable applications. Its patented dual-energy technology only requires one shot to produce three images (DR, bone, and tissue) without motion artifacts.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Ariceum Therapeutics’ Targeted Radiopharmaceutical 177Lu-satoreotide Exhibits Promising Clinical Response and Good Tolerability Profile in Patients with Advanced Neuroendocrine Tumours

Satoreotide combines Ariceum’s proprietary peptide satoreotide - a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SSTR2) - with the radioactive isotope ‘payload’ 177Lutetium. SSTR2 is a cell surface protein often overexpressed in certain cancers, including NETs and small cell lung cancer (SCLC).

New Hot Start Isothermal Mixes Boost Sensitivity, Specificity, and Speed of DNA Target Detection

Isothermal mixes are important in a range of isothermal amplification applications, including whole genome amplification, point-of-care assay development and testing, and strand displacement amplification for synthetic biology. However, a common issue with isothermal mixes is non-specific amplification — where primers bind to unintended DNA targets — because amplification often takes place at a fixed temperature which may favour non-specific primer interactions, contrary to PCR. Isothermal mixes can also lead to primer dimer formation, where primers associate with each other and are extended by the polymerase.

Branded Legacy Invests Heavily in Innovation and Growth with $540,000 Expansion

This strategic initiative underscores Branded Legacy's unwavering commitment to innovation, quality, and customer satisfaction. The expansion project is set to infuse over $500,000 worth of inventory into the company, reinforcing its position as a leader in the market.

Cue Biopharma Completes Patient Enrollment in Ph1b Head & Neck Cancer Trial

“Completing the enrollment of the recommended phase 2 dose patient expansion cohort is an important milestone as the data from this trial guides further development plans and associated discussions with the Food and Drug Administration (FDA),” said Daniel Passeri, chief executive officer of Cue Biopharma.

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Michelle Fraser, head of cell and gene therapy at Revvity, underscores the importance of providing broad access to this technology: "Base editing has been extensively demonstrated in numerous studies to safely and precisely control the correction of single base changes at multiple target sites, simultaneously. This streamlined approach simplifies complex multi-gene editing, holding great promise for the development of new cell therapies targeting rare inherited genetic diseases, cancer, and in the creation of universal donor cells as the foundation of allogeneic cell therapies."

By using this website you agree to accept Medical Device News Magazine Privacy Policy